China
Africa
Explore chapters and articles related to this topic
Breast disorders in children and adolescents
Published in Joseph S. Sanfilippo, Eduardo Lara-Torre, Veronica Gomez-Lobo, Sanfilippo's Textbook of Pediatric and Adolescent GynecologySecond Edition, 2019
Nirupama K. De Silva, Monica Henning
Primary carcinoma of the breast has been reported in 39 children between the ages of 3 and 19 years.11,78 Over 80% of these patients were diagnosed with juvenile secretory carcinoma, with the remainder having intraductal carcinoma. Juvenile secretory carcinoma has been reported in association with juvenile papillomatosis.11 Juvenile secretory carcinoma often has a thick-walled capsule, which may cause the lesion to appear cystic on ultrasound.78
Endometrial malignant lesions
Published in T. Yee Khong, Annie N. Y. Cheung, Wenxin Zheng, Richard Wing-Cheuk Wong, Hao Chen, Diagnostic Endometrial Pathology, 2019
T. Yee Khong, Annie N. Y. Cheung, Wenxin Zheng
Secretory carcinoma. Typically, secretory carcinoma consists of confluent villoglandular voluminous glands with glycogen-enriched subnuclear vacuoles (resembles secretory endometrium) and almost always well differentiated (Figure 9.24). This is different from endometrioid carcinoma with focal secretory changes, which is likely related to the progestin usage. In contrast, the secretory glands in secretory carcinoma are diffuse, which is not related to progestin application, although the detailed molecular mechanisms are unknown. Most secretory carcinomas occur in postmenopausal women without hormone therapy.
Surgical and other investigations
Published in John Dudley Langdon, Mohan Francis Patel, Robert Andrew Ord, Peter Brennan, Operative Oral and Maxillofacial Surgery, 2017
As tumours are increasingly studied at the molecular level, the list of identified tumour-specific and defining translocations grows by the year. Study of salivary gland tumours at the genetic level is one example where in recent times; new information gained from these studies has led to addition of a new entity to the classification, namely mammary analogue secretory carcinoma. Rather than this being a newly occurring tumour, it is most likely that these have previously been designated as acinic cell carcinoma. Information gained from molecular investigation may in future be used to provide prognostic information or guide treatment.
A Parotid Gland Mammary Analogue Secretory Carcinoma in a 4-Year-Old Boy: Case Report and Literature Review
Published in Fetal and Pediatric Pathology, 2023
Zhao Meng, Wu Si, Zhu Xiuli, Yueping Liu
The histologic features of the MASC reported herein are typical of those described in primary salivary gland tumors: Eosinophilic vacuolated cytoplasm within cystic, tubular, and/or papillary architecture indicative of true acinar differentiation, low-grade and pale nuclei, infrequent mitotic figures [17–20]. There is no prominent fibrosclerotic stroma and thick hyalinized fibrous septa. MASC and secretory carcinoma of the breast also have common immuno-histochemical findings such positivity for S100 and mammaglobin, usually with a diffuse and strong staining pattern [21], while being negative for ER/PR/Her2. STAT5 was also reported to be a useful marker in the differential diagnosis of MASC. Strauss et al. [22] indicated that the MASC expressed by STAT5 might be related to t(12;15)(p13;q25) chromosomal translocation. The expression of nuclear and cytoplasmic STAT5 immunoreactivity is not specific, as positivity for this marker is observed in acinic cell carcinoma (ACC) [1].
Heterogeneity of triple-negative breast cancer: understanding the Daedalian labyrinth and how it could reveal new drug targets
Published in Expert Opinion on Therapeutic Targets, 2022
Alberto Zambelli, Riccardo Sgarra, Rita De Sanctis, Elisa Agostinetto, Armando Santoro, Guidalberto Manfioletti
Established evidence clearly showed that TNBC is a unique disease, encompassing multiple entities characterized by histopathological, transcriptomic, and (epi)genomic heterogeneity. From an histopathological point of view, the majority of TNBCs are classified as invasive mammary carcinomas (typically invasive ductal carcinomas), prevailing the poor tumor differentiation and the presence of stromal lymphocytes along with metaplastic elements [2]. Notwithstanding these main characteristics, the TNBCs also recognize rare cases of low-grade neoplasms, including the triple-negative (TN) breast neoplasia (atypical or not microglandular adenosis and acinic cell carcinoma) and the salivary gland-like tumors of the breast as the mucoepidermoid carcinoma, the polymorphous low-grade adenocarcinoma, the adenoid cystic carcinoma, and the secretory carcinoma) [3]. Notably, both the adenoid cystic carcinoma and the secretory carcinoma constitute two rare but unique TN subtypes with pathognomonic genetic alterations of MYB-NFIB and ETV6- NTRK3 fusion genes, respectively [4,5].
Pitfalls and controversies in pathology impacting breast cancer management
Published in Expert Review of Anticancer Therapy, 2020
Woo Gyeong Kim, Margaret C. Cummings, Sunil R. Lakhani
The increasing recognition of new and special subtypes of breast cancer, such as invasive micropapillary carcinoma, or the low-grade triple-negative breast carcinomas, such as adenoid cystic carcinoma and secretory carcinoma, raises questions about the validity of using conventional histological grading for such tumors, despite this being an established marker of prognosis for carcinomas of no-special type. With emerging molecular data concerning breast cancer and its precursors, there is pressure on pathologists to carry out and report on a variety of biomarkers, not all of which have been as well as established as estrogen receptor protein (ER) or Her2. Ki-67 and PDL-1 are just two biomarkers which are already dividing the pathology and oncology communities. The use of pre-surgical neoadjuvant systemic therapies (NAST) using endocrine therapy, chemotherapy, or both has created challenges in providing conventional prognostic data concerning histological type, grade, and stage of cancers, including lymph node status.